Oritavancin  (PDF Version)

Antibiotic Class:

Glycopeptide

Antimicrobial Spectrum:

Staphylococcus aureus (Oritavancin susceptible), Coagulase negative Staphylococci, Streptococcus pneumoniae, Streptococcus spp., Enterococcus spp. (Oritavancin susceptible), C. jeikeium, Clostridium spp., L. monocytogenes, Actinomyces

Mechanism of Action:

Oritavancin inhibits the transgycosylation of bacterial cell wall biosynthesis

Pharmacodynamics:

No data

Pharmacokinetics:

Cmax: 23.6mg/L (after 3mg/kg dose); Half-life: 132-356 hours; Volume of distribution: 0.65-1.92L/kg

Adverse Effects:

Skin: Hypersensitivity

Pulmonary: Pulmonary embolism

Otic: Ototoxicity

Other: Tremors

Dosage:

Not commercially available

Disease state based dosing:

Not determined

Contraindications/Warnings/Precautions:

Not yet determined

Drug Interactions:

Unknown

Pregnancy:

Unknown

Monitoring Requirements:

Therapeutic:  Culture and sensitivities, serum levels, signs and symptoms of infection, white blood cell count

Brand names/Manufacturer:  Not available